Skip to main content

Advertisement

SpringerLink
Log in

Acquired factor V inhibitors: a systematic review

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The occurrence of an inhibitor against coagulation factor V (FV) is a rare but challenging condition, which may span from asymptomatic laboratory abnormalities to potentially life-threatening bleeding. The onset of FV inhibitors has been associated most frequently in the past with the patients’ exposure to topical bovine thrombin administered during surgery procedures. However, since this preparation is no longer used, in this systematic review we have only focused on non-bovine thrombin-related FV inhibitor cases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Knoble P, Lechner K (1998) Acquired factor V inhibitors. Bailliere’s Clin Haematol 11:305–318

    Article  Google Scholar 

  2. Emori Y, Sakugawa M, Niiya K et al (2002) Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis 13:555–559

    Article  PubMed  CAS  Google Scholar 

  3. Wiwanitkit V (2006) Spectrum of bleeding in acquired factor V inhibitor: a summary of 33 cases. Clin Appl Thromb Hemost 12:485–488

    Article  PubMed  CAS  Google Scholar 

  4. Morris CJ, Curris N (2009) Acquired factor V inhibitor in a critically ill patient. Anaesthesia 64:1014–1017

    Article  PubMed  CAS  Google Scholar 

  5. Franchini M, Gandini G, Di Paolantonio T et al (2005) Acquired hemophilia A: a concise review. Am J Hematol 80:55–63

    Article  PubMed  CAS  Google Scholar 

  6. Franchini M, Targher G, Montagnana M, Lippi G (2008) Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 395:14–18

    Article  PubMed  CAS  Google Scholar 

  7. Ortel T (1999) Clinical and laboratory manifestations of antifactor V antibodies. J Lab Clin Med 133:326–334

    Article  PubMed  CAS  Google Scholar 

  8. Favaloro EJ, Bonar R, Duncan E et al (2006) Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 96:73–78

    Google Scholar 

  9. Favaloro EJ, Posen J, Ramakrishna R et al (2004) Factor V inhibitors: rare or not so uncommon? A multilaboratory investigation. Blood Coagul Fibrinolysis 15:637–647

    Article  PubMed  Google Scholar 

  10. Miesbach W, Voigt J, Peetz D, Scharrer I (2003) Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. Med Klin 98:339–343

    Google Scholar 

  11. Lucia JF, Aguilar C (2005) A case of an asymptomatic idiopathic inhibitor to coagulation factor V. Haemophilia 11:178–180

    Article  PubMed  CAS  Google Scholar 

  12. Takahashi H, Fuse I, Abe T, Yoshino N, Aizawa Y (2003) Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis 14:87–93

    Article  PubMed  Google Scholar 

  13. Koyama JA, Saito T, Kusano T, Hirosawa S (1995) Factor V inhibitor associated with Sjogren’s syndrome. Br J Haematol 89:893–896

    Article  PubMed  CAS  Google Scholar 

  14. Streiff MB, Ness PM (2002) Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 42:18–26

    Article  PubMed  Google Scholar 

  15. Banninger H, Hardegger T, Tobler A et al (1993) Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 85:528–532

    Article  PubMed  CAS  Google Scholar 

  16. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH (2001) Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233:88–96

    Article  PubMed  CAS  Google Scholar 

  17. Lu L, Liu Y, Wei J, Zhang L, Yang R (2004) Acquired inhibitor of factor V: first report in China and literature review. Haemophilia 10:661–664

    Article  PubMed  CAS  Google Scholar 

  18. Leus B, Devreese K, Van den Bossche J, Malfait R (2006) Factor V inhibitor: case report. Blood Coagul Fibrinolysis 17:585–587

    Article  PubMed  Google Scholar 

  19. Kajitani M, Ozdemir A, Aguinaga M, Jazieh AR, Flick JT, Antakli T (2000) Hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 15:378–382

    Article  PubMed  CAS  Google Scholar 

  20. Bowman LJ, Anderson CD, Chapman WC (2010) Topical recombinant human thrombin in surgical hemostasis. Semin Thromb Hemost 36:477–484

    Article  PubMed  CAS  Google Scholar 

  21. Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101:852–859

    PubMed  CAS  Google Scholar 

  22. Feinstein DI (1978) Acquired inhibitors of factor V. Thromb Haemost 39:663–674

    PubMed  CAS  Google Scholar 

  23. Ferguson JH, Johnston CL, Howell DA (1958) A circulating inhibitor (anti-AcG) specific for the labile factor-V of the blood-clotting mechanism. Blood 13:382–397

    Google Scholar 

  24. Lopez V, Pflughaupt R, Butler R (1968) A specific inhibitor of human clotting factor V. Acta Haematol 40:275–285

    Article  PubMed  CAS  Google Scholar 

  25. Hundley DA, Duncan BM (1969) A circulating anticoagulant specific for factor V. Pathology 1:265–272

    Article  Google Scholar 

  26. Feinstein DI, Rapaport SI, McGehee WG, Patch MJ (1970) Factor V anticoagulants: clinical, biochemical and immunological observations. J Clin Invest 49:1578–1588

    Article  PubMed  CAS  Google Scholar 

  27. Feinstein DI, Rapaport SI, Chong MMY (1973) Factor V inhibitor: report of a case, with comments on a possible effect of streptomycin. Ann Intern Med 78:385–388

    PubMed  CAS  Google Scholar 

  28. Onuora CA, Lindenbaum J, Nossel HL (1973) Massive hemorrhage associated with circulating antibodies to factor V. Am J Med Sci 265:407–417

    Article  PubMed  CAS  Google Scholar 

  29. Nilsson IM, Hedner U, Ekberg M, Denneberg T (1974) A circulating anticoagulant against factor V. Acta Med Scand 195:73–77

    Article  PubMed  CAS  Google Scholar 

  30. Stenbjerg S, Husted S, Mygind K (1975) A circulating factor V inhibitor: possible side effect of treatment with strepromycin. Scand J Haematol 14:280–285

    Article  PubMed  CAS  Google Scholar 

  31. Crowell EB (1975) Observations on a factor V inhibitor. Br J Haematol 29:397–404

    Article  PubMed  Google Scholar 

  32. Bryning K, Leslie J (1977) Factor V inhibitor and bullous pemphigoid. Br Med J 2:677–678

    Article  PubMed  CAS  Google Scholar 

  33. Coots MC, Muhleman AF, Glueck HI (1978) Hemorrhagic death associated with a high titer factor V inhibitor. Am J Hematol 4:193–206

    Article  PubMed  CAS  Google Scholar 

  34. Lane TA, Shapiro SS, Burka ER (1978) Factor V antibody and disseminated intravascular coagulation. Ann Intern Med 89:182–185

    PubMed  CAS  Google Scholar 

  35. Lust A, Bellon A (1978) A circulating anticoagulant against factor V. Acta Clin Belg 33:62–65

    PubMed  CAS  Google Scholar 

  36. Chediak J, Ashenhurst JB, Garlick I, Desser RK (1980) Sucessful management of bleeding in a patient with factor V inhibitor by platelet transfusion. Blood 56:835–841

    PubMed  CAS  Google Scholar 

  37. Abe T, Kazama M, Itokazu K et al (1980) A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII bypassing activity preparation FEIBA. Rinsho Ketsueki 21:1664–1673

    PubMed  CAS  Google Scholar 

  38. Hida K, Sakamoto S, Takaku F et al (1980) A case of acquired coagulopathy due to factor V inhibitor. Rinsho Ketsueki 21:1589–1596

    Google Scholar 

  39. Lerolle D, Dreyer-Dufer C, Allain JP (1981) A circulating inhibitor specific to factor V. Clinical, biological and therapeutic study. Nouv Presse Med 10:1483–1487

    PubMed  CAS  Google Scholar 

  40. Kuto M, Izuchi Y, Deguchi K, Morito T, Lee C, Wada H (1981) An inhibitor against factor V occurring postoperatively in a case of pancreatic cancer. Nippon Ketsueki Gakkai Zasshi 44:938–950

    PubMed  CAS  Google Scholar 

  41. Vickars LM, Coupland RW, Naiman SC (1985) The response of an acquired factor V inhibitor to activated factor IX concentrate. Transfusion 25:51–53

    Article  PubMed  CAS  Google Scholar 

  42. Chong LL, Wong YC (1985) A case of factor V inhibitor. Am J Hematol 19:395–399

    Article  PubMed  CAS  Google Scholar 

  43. Chiu HC, Rao AK, beckett C, Colman RW (1985) Immune complexes containing factor V in a patient with an acquired neutralizing antibody. Blood 65:810–818

    PubMed  CAS  Google Scholar 

  44. Nesheim ME, Nichols WL, Cole TL et al (1986) Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77:405–415

    Article  PubMed  CAS  Google Scholar 

  45. Brandt J, Britton A, Kraut E (1986) A spontaneous factor V inhibitor with unexpected laboratory features. Arch Pathol Lab Med 110:224–227

    PubMed  CAS  Google Scholar 

  46. Lazarchick J, Wolff M, Pepkowitz SH, Kizer J, Romein LA (1986) Factor V inhibitor associated with immune complex formation. Arch Pathol Lab Med 110:448–451

    PubMed  CAS  Google Scholar 

  47. Massignon D, Roullit S, Espinouse D, Coeur P (1989) Occurrence of a circulating anticoagulant, factor V inhibitor after surgical intervention. Ann Fr Anesth Reanim 81:70–72

    Google Scholar 

  48. Okajima A, Horii J, Nasu K et al (1989) Factor V inhibitor with double cancer. Rinsho Ketsueki 30:514–519

    PubMed  CAS  Google Scholar 

  49. Grigg AP, Dauer R, Thurlow PJ (1989) Bleeding due to an acquired inhibitor of platelet associated factor V. Aust NZ J Med 19:310–314

    CAS  Google Scholar 

  50. Taillan B, Fuzibet JB, Vinti H et al (1989) Factor V inhibitor in celiac disease. Am J Med 87:360

    Article  PubMed  CAS  Google Scholar 

  51. Gordon B, haire W, Duggan M, Langnas A (1991) Factor V inhibitor developing after liver transplantation in a 3-year-old child. Pediatrics 88:156–159

    PubMed  CAS  Google Scholar 

  52. Buclin T, Schmidt PM, Hauert J, Winkel L, Chapuis G, Bachmann F (1992) Acquired factor V inhibitor treated with intravenous immunoglobulins. Schweiz Med Wochenschr 122:1968–1970

    PubMed  CAS  Google Scholar 

  53. Kapur A, Kelsey PR, Isaacs PET (1993) Factor V inhibitor in thrombosis. Am J Hematol 42:384–388

    Article  PubMed  CAS  Google Scholar 

  54. Smid WM, de Wolf JTM, Nijland JH, Bom VJJ, van der Meer J (1994) Sever bleeding caused by an inhibitor to coagulation factor V: a case report. Blood Coagul Fibrinolysis 5:133–137

    Article  PubMed  CAS  Google Scholar 

  55. Denis A, Baudeau C, Verdy E, Couderc R, Rondeau E, Sraer JD (1995) Acquired circulating anticoagulant with anti-factor V activity in AIDS: first case report. Nouv Rev Fr Hematol 37:165–169

    PubMed  CAS  Google Scholar 

  56. Tribl B, Knobl P, Derfler K et al (1995) Rapid elimination of a high-titer spontanoues factor V antibody by extracorporeal antibody-based immunoadsorption and immunosuppression. Ann Hematol 71:199–203

    Article  PubMed  CAS  Google Scholar 

  57. George S, Nagabhushana MS, Cyran EM (1995) Coagulopathy due to an acquired factor V inhibitor and subsequently thrombosis. Am J Hematol 49:98–100

    Article  PubMed  CAS  Google Scholar 

  58. Suehisa E, Toku M, Akita N et al (1995) Study of an antibody against F1F2 fragment of human factor V in a patient with Hashimoto’s disease and bullous pemphigoid. Thromb Res 77:63–68

    Article  PubMed  CAS  Google Scholar 

  59. Fu YX, Kaufman R, Rudolph AE, Collum SE, Blinder MA (1996) Multimodality therapy of an acquired factor V inhibitor. Am J Hematol 51:315–318

    Article  PubMed  CAS  Google Scholar 

  60. Brickner LA, Scannell KA, Sahud MA (1996) Acquired factor V inibito in a patient with acquired human immunodeficiency syndrome. Am J Hematol 52:332–333

    Article  PubMed  CAS  Google Scholar 

  61. Van Spronsen DJ, Oosting JD, Hoffmann JJML, Breed WPM (1998) Factor V inhibitor associated with cold agglutinin disease. Ann Hematol 76:49–50

    Article  PubMed  Google Scholar 

  62. Kamphuisen PW, Haan J, Rosekrans PCM, van der Meer FJM (1998) Deep-vein thrombosis and coumarin skin necrosis associated with a factor V inhibitor with lupus-like features. Am J Hematol 57:176–178

    Article  PubMed  CAS  Google Scholar 

  63. Smith JD, Sindhi R, Rogers R, Lazarchick J (1998) Factor V inhibitor in a liver transplant patient associated with porcine xenoperfusion. Ann Clin Lab Sci 28:280–282

    PubMed  CAS  Google Scholar 

  64. Shastri KA, Ho C, Logue G (1999) An acquired factor V inhibitor: clinical and laboratory features. J Med 30:357–366

    PubMed  CAS  Google Scholar 

  65. Leroy-Matheron C, Mallat A, Duvoux C et al (1999) Inhibitor against coagulation factor V after liver transplantation. Transplantation 68:1054–1056

    Article  PubMed  CAS  Google Scholar 

  66. Jansen M, Schmaldienst S, Banyai S et al (2001) Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb). Br J Haematol 112:91–97

    Article  PubMed  CAS  Google Scholar 

  67. Bayani N, Rugina M, Haddad-Vergnes L, Lelong F (2002) High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. Am J Hematol 71:33–36

    Article  PubMed  Google Scholar 

  68. Takaku T, Kuriyama Y, Shoji N et al (2002) Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis. Rinsho Ketsueki 43:1050–1054

    Google Scholar 

  69. Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A (2002) Isolation and characterization of an antifactor V antibody causino activated protein C resistance from a patient with severe thrombotic manifestations. Blood 99:3985–3992

    Google Scholar 

  70. Hasegawa M, Tanaka T, Kii T et al (2003) Acquired inhibitor against coagulation factor V with severe hematuria. Rinsho Ketsueki 44:933–939

    PubMed  Google Scholar 

  71. Okoshi Y, Akiyama H, Inoue T et al (2003) A long-lasting idiopathic factor V inhibitor. Rinsho Ketsueki 44:14–18

    PubMed  Google Scholar 

  72. Ajzner E, Balogh I, Haramura G et al (2003) Anti-factor V auto-antibody in the plasma and platelets of a patient with repeated gastrointestinal bleeding. J Thromb Haemost 1:943–999

    Article  PubMed  CAS  Google Scholar 

  73. de Raucourt E, Barbier C, Sinda P, Dib M, Peltier JY, Ternisien C (2003) High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am J Hematol 74:187–190

    Article  PubMed  Google Scholar 

  74. Lian EC, Tzakis AG, Andrews D (2004) Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. Am J Hematol 77:363–365

    Article  PubMed  Google Scholar 

  75. Tukić L, Stamatović D, Tarabar O, Elez M, Zorić M, Mandić-Radić S (2005) Acquired factor V inhibitors in a polytraumatized patient. Vojnosanit Pregl 62:587–590

    Article  PubMed  Google Scholar 

  76. Godart B, Boinot C, Remblier C, Hajjar A, Beauchant M (2006) Acquired factor V inhibitor associated with valproic acid use in a cirrhotic patient. Gut 55:134–135

    Article  PubMed  CAS  Google Scholar 

  77. Perdekamp MT, Rubenstein DA, Jesty J, Hultin MB (2006) Platelet factor V supports hemostasis in a patient with an acquired factor V inhibitor, as shown by prothrombinase and tenase assys. Blood Coagul Fibrinolysis 17:593–597

    Article  PubMed  Google Scholar 

  78. Gacina P, Kusec R, Carzavec D, Raic B, Stancic V (2006) Acquired factor V inhibitor: a case report. Acta Clin Croat 45:199–201

    Google Scholar 

  79. Endo H, Kawauchi K, Tomimatsu M et al. (2007) Acquired factor V inhibitor responsive to corticosteroids in a patient with double cancers. Intern Med 46:621–625

    Google Scholar 

  80. Maughan EO, Wilson J, Wilde JT (2007) Spontaneous resolution of acquired factor V inhibitor associated with ovarian carcinoma. Int J Lab Hematol 29:316–319

    Article  PubMed  CAS  Google Scholar 

  81. Milojkovic D, Patel R, Ford E, Arya R, Mufti G (2007) Acquired factor V inhibitor after hematopoietic stem cell transplantation. Thromb Haemost 98:685–687

    PubMed  CAS  Google Scholar 

  82. Shimizu I, Ichikawa N, Yotsumoto M, Sumi M, Ueno M, Kobayashi H (2008) High-titer idiopathic acquired factor V inhibitor patient showing decreased activities of multiple coagulation factors. Rinsho Ketsueki 49:413–416

    PubMed  Google Scholar 

  83. Jeimy SB, Krakow EF, Fuller N, Tasneem S, Hayward CPM (2008) An acquired factor V inhibitor associated with defective factor V function, storage and binding to multimerin 1. J Thromb Haemost 6:395–397

    PubMed  CAS  Google Scholar 

  84. Lebrun A, Leroy-Matheron C, Arlet JB, Bartolucci P, Michel M (2008) Successful treatment with rituximab in a patient with an acquired factor V inhibitor. Am J Hematol 83:163–164

    Article  PubMed  Google Scholar 

  85. William BM (2008) Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor. Blood Coagul Fibrinolysis 19:327–328

    Article  PubMed  Google Scholar 

  86. Gadelha T, Aquino JHW, Silva EA, Santos FL, de Oliveira MHFC (2008) The diversity in clinical presentation of acquired factor V inhibitor, two case reports. Acta Haematol 119:108–110

    Article  PubMed  Google Scholar 

  87. Kindler S, Siegemund T, Fuhrer D, Petros S (2008) Thrombin generation assay in a patient with acquired factor V inhibitor. J Thromb Haemost 6:1985–1987

    Article  PubMed  CAS  Google Scholar 

  88. Shanmugam H, Jayaranee S, Eow GI (2010) A case report of an acquired inhibitor to coagulation factor V. Haemophilia [Epub ahead of print]

  89. Tessier-Marteau A, Croquefer S, Meziani F, Cau S, Asfar P, Macchi L (2010) Acquired factor V inhibitor in a context of sepsis and disseminated intravascular coagulation. Am J Hematol 85:145–146

    PubMed  Google Scholar 

  90. Franchini M, Lippi G (2010) Recombinant activated factor VII: mechanisms of action and current indications. Semin Thromb Haemost 36:485–492

    Article  CAS  Google Scholar 

  91. Yu Z, Lennon VA (1999) Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 340:227–228

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servizio di Immunoematologia e Medicina Trasfusionale, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

    Massimo Franchini & Giuseppe Lippi

  2. U.O di Diagnostica Ematochimica, Dipartimento di Patologia e Medicina di Laboratorio, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

    Massimo Franchini & Giuseppe Lippi

Authors
  1. Massimo Franchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Lippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Franchini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franchini, M., Lippi, G. Acquired factor V inhibitors: a systematic review. J Thromb Thrombolysis 31, 449–457 (2011). https://doi.org/10.1007/s11239-010-0529-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-010-0529-6

Keywords

Search

Navigation